- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02583685
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (SWITCH-1)
August 27, 2021 updated by: Humanity and Health Research Centre
Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
160
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chen WANG, MD, PhD
- Phone Number: +85228613777
- Email: doc_chengwang@126.com
Study Contact Backup
- Name: Yudong WANG, PhD
- Phone Number: +85228613777
- Email: ydwang@connect.hku.hk
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100039
- Recruiting
- Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital
-
Principal Investigator:
- Guofeng Chen, MD
-
Principal Investigator:
- George KK Lau, MD
-
Contact:
- Guofeng Chen, MD
- Phone Number: (8610)66933427
- Email: guofengchen302@163.com
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 00852
- Recruiting
- Humanity and Health GI and Liver Centre
-
Contact:
- George KK Lau, MD
- Phone Number: (852)28613777
- Email: gkklau@netvigator.com
-
Principal Investigator:
- George KK Lau, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Individuals with chronic HCV GT1b infection;
- HCV RNA ≥ 10000 IU/mL at screening;
- Received 4 weeks pegylated interferon plus ribavirin (PR4) therapy and are intolerant to PR4;
- Cirrhosis determination; a liver biopsy may be required;
- Use of highly effective contraception methods if female of childbearing potential or sexually active male;
Exclusion Criteria:
- Pregnant or nursing female or male with pregnant female partner;
- HIV or HBV co-infection;
- Hematologic or biochemical parameters at Screening outside the protocol- specified requirements;
- Active or recent history (≤ 1 year) of drug or alcohol abuse;
- History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PR4 + LDV/SOF + ASV 4 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + SMV 4 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + ASV 6 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + SMV 6 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + ASV 8 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + SMV 8 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + ASV 12 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Other Names:
|
Experimental: PR4 + LDV/SOF + SMV 12 wk
Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
|
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy
Time Frame: Post treatment Week 12
|
SVR12 is defined as HCV RNA < lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.
|
Post treatment Week 12
|
Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment adherence
Time Frame: Baseline to Week 12
|
To evaluate the proportion of patients adherent to therapy (both on-treatment adherence and treatment discontinuation)
|
Baseline to Week 12
|
Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
Change in health related quality of life evaluated with questionnaires
Time Frame: Up to Posttreatment Week 24
|
To evaluate the change in health-related quality of life during and after treatment with questionnaires
|
Up to Posttreatment Week 24
|
Change in mental health evaluated with questionnaires
Time Frame: Up to Posttreatment Week 24
|
To evaluate the change in mental health during and after treatment with questionnaires
|
Up to Posttreatment Week 24
|
Liver disease progression
Time Frame: Up to 10 years
|
Liver disease progression is a composite endpoint measured by laboratory parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin, platelets, prothrombin time (PT) and α-fetoprotein) and observed or reported clinical signs and symptoms.
|
Up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: George Lau, Humanity and Health GI and Liver Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Anticipated)
October 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
October 12, 2015
First Submitted That Met QC Criteria
October 20, 2015
First Posted (Estimate)
October 22, 2015
Study Record Updates
Last Update Posted (Actual)
August 30, 2021
Last Update Submitted That Met QC Criteria
August 27, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis, Chronic
- Hepatitis
- Infections
- Hepatitis C
- Hepatitis C, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites
- Immunologic Factors
- Protease Inhibitors
- Interferon-alpha
- Ribavirin
- Peginterferon alfa-2a
- Simeprevir
- Ledipasvir, sofosbuvir drug combination
Other Study ID Numbers
- H&H_SWITCH-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C Infection
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Gilead SciencesCompletedChronic Hepatitis C InfectionNew Zealand
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Janssen R&D IrelandTerminated
-
Vertex Pharmaceuticals IncorporatedTerminatedChronic Hepatitis C Virus InfectionUnited States, New Zealand
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on PR4 + LDV/SOF + ASV 4 wk
-
Humanity and Health Research CentreEmory University; Beijing 302 HospitalCompleted